PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 20, 20250 citationsOpen Access

Figure 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer

View Full Paper
BIBunpei IsodaMSMasanobu ShigaSKShuya Kandori

Key Points

  • Patients with immune-related adverse events had different survival outcomes compared to those without them.
  • Kaplan–Meier curves indicated variations in overall survival and progression-free survival between groups.
  • Multivariable analysis identified additional prognostic factors affecting survival outcomes in the ICI–TKI group.
  • The study emphasizes the importance of considering immune-related adverse events in treatment evaluations.

Abstract

Survival outcomes and multivariable analysis of prognostic factors in the ICI–TKI group. A, Kaplan–Meier curves for OS and PFS. The results of a survival analysis conducted on the ICI–TKI group with and without irAEs. The red line represents the patient group without irAEs, and the blue line represents the patient group with irAEs. B, Multivariable analysis of OS and PFS of the ICI–TKI group. NA, not available.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Isoda et al. (2025) studied this question.

synapsesocial.com/papers/68d46fcd31b076d99fa69f10https://doi.org/10.1158/2767-9764.30162547
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Figure 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer2025
  2. 2Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer2025
  3. 3Data from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer2025
  4. 4Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer2025 · 1 citations
  5. 5Table 4 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer2025